Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication

NCT ID: NCT05128305

Last Updated: 2021-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

276 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-01

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatic encephalopathy is the most common complication after TIPS, and hepatic encephalopathy occurs in almost all portosystemic shunts. For patients with severe upper gastrointestinal bleeding or refractory ascites in the decompensated chronic hepatitis B, transjugular intrahepatic portosystemic shunt (TIPS) is a very effective treatment. However, due to the severe complications such as hepatic encephalopathy after TIPS, the clinical application of TIPS is limited. Literature studies have shown that the incidence of encephalopathy after TIPS is about 35%. TIPS reduces the portal vena blood flow into the liver by establishing a new channel. But at the same time, the toxic substances from the gastrointestinal tract and other organs do not enter the liver to detoxify, and are more likely to enter the brain, leading to hepatic encephalopathy.

Moreover, studies have found that the liver and the intestine originate from the same germ layer and are closely related to each other in anatomy and function. There are a large number of microorganisms living in the intestinal tract. Normally, the intestinal tract, as the first defense of the human body, can effectively prevent bacteria and their products from entering the bloodstream. In cirrhosis and portal hypertension, blood return disorder causes intestinal damage. A series of microbes and product endotoxins such as gram-negative bacteria will enter the blood through the injury, and the toxins in the peripheral blood will enter the brain and cause hepatic encephalopathy happened.

The research team's early treatment plan with integrated traditional Chinese and Western medicine proved that it greatly reduced the incidence of hepatic encephalopathy after TIPS. And improve the clinical symptoms and signs of patients with liver cirrhosis, and improve the quality of life and survival of patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Encephalopathy Cirrhosis, Liver Portosystemic Shunt

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1

traditional chinese medicine 1 and traditional chinese medicine 2 simulant

Group Type EXPERIMENTAL

traditional Chinese medicine1 and traditional Chinese medicine 2

Intervention Type DRUG

We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS

group 2

traditional chinese medicine 1 simulant and traditional chinese medicine 2

Group Type EXPERIMENTAL

traditional Chinese medicine1 and traditional Chinese medicine 2

Intervention Type DRUG

We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS

group 3

traditional chinese medicine 1 and traditional chinese medicine 2

Group Type EXPERIMENTAL

traditional Chinese medicine1 and traditional Chinese medicine 2

Intervention Type DRUG

We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS

group 4

traditional chinese medicine 1 simulant and traditional chinese medicine 2 simulant

Group Type PLACEBO_COMPARATOR

traditional Chinese medicine1 and traditional Chinese medicine 2

Intervention Type DRUG

We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

traditional Chinese medicine1 and traditional Chinese medicine 2

We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

traditional Chinese medicine1 simulant and traditional Chinese medicine 2 simulant

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* TIPS treatment criteria in line with the 2017 edition of the "Expert Consensus on Transjugular Intrahepatic Portosystemic Shunt" were selected to include patients with hepatitis B cirrhosis and Child-pugh grade A and B after TIPS surgery.
* Patients with liver cirrhosis, portal hypertension, bleeding from esophagus and gastric varices; refractory pleural and ascites due to liver cirrhosis; incomplete portal vein/localized thrombosis in liver cirrhosis or primary and secondary prevention of cirrhosis, portal hypertension, esophagus and gastric varices bleeding.

Exclusion Criteria

* Severe blood coagulation disorder (PTA≤20%) or platelets lower than 30×109/L;
* Child-pugh classification of liver function C;
* Those with respiratory and circulatory dysfunction;
* Those whose systemic or focal infections have not been effectively controlled;
* Patients with moderate to severe malnutrition;
* Extensive primary or metastatic liver malignant tumors;
* Those who are highly allergic to the products and drugs used in the treatment process.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Qianfoshan Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lili Cao

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

he First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Jinan, Shandong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

fengyan Wang, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CT-2020-1230

Identifier Type: -

Identifier Source: org_study_id